Peptides as therapeutics with enhanced bioactivity

Current Medicinal Chemistry

Volumn 19, Issue 26, 2012, Pages 4451-4461

  Goodwin, D ^a   Simerska, P ^a   Toth, I ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Bioavailability; Clinical trials; Drug delivery; Immunogenicity; Manufacture; Peptide; Peptide drug; Peptide synthesis; Peptide therapeutic; Vaccine

Indexed keywords

ALPHA2B INTERFERON; ANGIOPEPTIN; CYCLOSPORIN A; DEGARELIX; DESMOPRESSIN; DESULFATOHIRUDIN; ECALLANTIDE; ENFUVIRTIDE; EXENDIN 4; GONADORELIN; ICATIBANT; LEUCINE ENKEPHALIN[2 DEXTRO ALANINE 6 ARGININE]; OMEGA CONOTOXIN MVIIA; OXYTOCIN; PARATHYROID HORMONE[1-34]; PEPTIDE VACCINE; PEPTIDOMIMETIC AGENT; PRAMLINTIDE; RECOMBINANT HUMAN INSULIN; SALCATONIN; VANCOMYCIN;

CYCLIZATION; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; ENCAPSULATION; GLYCOSYLATION; HUMAN; LIPOPHILICITY; NONHUMAN; PEPTIDE SYNTHESIS; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; HUMANS; PEPTIDES; VACCINES, SUBUNIT;

EID: 84868020147     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712803251548     Document Type: Review

References (153)

1. Reichert, J.; Pechon, P.; Tartat, A.; Dunn, M.K. Development trends for peptide therapeutics: A comprehensive quantitative analysis of peptide therapeutics in clinical development.; Peptide Therapeutics Foundation: 2010.
2. Bray, B.L. Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat. Rev. Drug Discov., 2003, 2, 587-593.
3. Thayer, A.M. Making peptides at large scale. Chem. Eng. News, 2011, 89, 21-25.
4. Guzman, F.; Barberis, S.; Illanes, A. Peptide synthesis: Chemical or enzymatic. Electron. J. Biotechnol., 2007, 10, 279-314.
5. Du Vigneaud, V.; Ressler, C.; Swan, J.M.; Roberts, C.W.; Katsoyannis, P.G.; Gordon, S. The synthesis of an octapeptide amide with the hormonal activity of oxytocin. J. Am. Chem. Soc., 1953, 75, 4879-4880.
6. Merrifield, R.B. Solid phase peptide synthesis i. The synthesis of a tetrapeptide. J. Am. Chem. Soc., 1963, 85, 2149-2154.
7. Schnolzer, M.; Alewood, P.; Jones, A.; Alewood, D.; Kent, S.B.H. In situ neutralization in boc-chemistry solid phase peptide synthesis - rapid, high yield assembly of difficult sequences. Int. J. Pept. Res. Ther., 2007, 13, 31-44.
8. Chantell, C.A.; Onaiyekan, M.A.; Menakuru, M. Fast conventional Fmoc solid-phase peptide synthesis: A comparative study of different activators. J. Pept. Sci., 2012, 18, 88-91.
9. Steinberg, M. Degarelix: A gonadotropin-releasing hormone antagonist for the management of prostate cancer. Clin. Ther., 2009, 31, 2312-2331.
10. Verlander, M. Industrial applications of solid-phase peptide synthesis - a status report. Int. J. Pept. Res. Ther., 2007, 13, 75-82.
11. Yu, H.M.; Chen, S.T.; Wang, K.T. Enhanced coupling efficiency in solid-phase peptide-synthesis by microwave irradiation. J. Org. Chem., 1992, 57, 4781-4784.
12. Rizzolo, F.; Sabatino, G.; Chelli, M.; Rovero, P.; Papini, A.M. A convenient microwave-enhanced solid-phase synthesis of difficult peptide sequences: Case study of gramicidin a and CSF114(glc). Int. J. Pept. Res. Ther., 2007, 13, 203-208.
13. Dawson, P.E.; Muir, T.W.; Clark-Lewis, I.; Kent, S.B. Synthesis of proteins by native chemical ligation. Science, 1994, 266, 776-779.
14. Offer, J.; Boddy, C.N.C.; Dawson, P.E. Extending synthetic access to proteins with a removable acyl transfer auxiliary. J. Am. Chem. Soc., 2002, 124, 4642-4646.
15. Spasser, L.; Kumar, K.S.A.; Brik, A. Scope and limitation of side-chain assisted ligation. J. Pept. Sci., 2011, 17, 252-255.
16. Hojo, K.; Maeda, M.; Kawasaki, K. Solid-phase peptide synthesis in water. Part 3: A water-soluble N-protecting group, 2-[phenyl(methyl)sulfonio] ethoxycarbonyl tetrafluoroborate, and its application to solid phase peptide synthesis in water. Tetrahedron, 2004, 60, 1875-1886.
17. Hojo, K.; Ichikawa, H.; Onishi, M.; Fukumori, Y.; Kawasaki, K. Peptide synthesis 'in water' by a solution-phase method using water-dispersible nanoparticle Boc-amino acid. J. Pept. Sci., 2011, 17, 487-492.
18. Wohr, T.; Wahl, F.; Nefzi, A.; Rohwedder, B.; Sato, T.; Sun, X.C.; Mutter, M. Pseudo-prolines as a solubilizing, structure-disrupting protection technique in peptide synthesis. J. Am. Chem. Soc., 1996, 118, 9218-9227.
19. Heinlein, C.; Silva, D.V.; Troster, A.; Schmidt, J.; Gross, A.; Unverzagt, C. Fragment condensation of C-terminal pseudoproline peptides without racemization on the solid phase. Angew. Chem. Int. Ed., 2011, 50, 6406-6410.
20. Frutos, S.; Tulla-Puche, J.; Albericio, F.; Giralt, E. Chemical synthesis of F-19-labeled HIV-1 protease using Fmoc-chemistry and ChemMatrix resin. Int. J. Pept. Res. Ther., 2007, 13, 221-227.
21. Garcia-Martin, F.; Quintanar-Audelo, M.; Garcia-Ramos, Y.; Cruz, L.J.; Gravel, C.; Furic, R.; Cote, S.; Tulla-Puche, J.; Albericio, F. ChemMatrix, a poly(ethylene glycol)-based support for the solid-phase synthesis of complex peptides. J. Comb. Chem., 2006, 8, 213-220.
22. Garcia-Martin, F.; White, P.; Steinauer, R.; Cote, S.; Tulla-Puche, J.; Albericio, F. The synergy of ChemMatrix resin (R) and pseudoproline building blocks renders RANTES, a complex aggregated chemokine. Biopolymers, 2006, 84, 566-575.
23. Kassem, T.; Sabatino, D.; Jia, X.; Zhu, X.X.; Lubell, W.D. To rink or not to rink amide link, that is the question to address for more economical and environmentally sound solid-phase peptide synthesis. Int. J. Pept. Res. Ther., 2009, 15, 211-218.
24. Agyei, D.; Danquah, M.K. Industrial-scale manufacturing of pharmaceutical-grade bioactive peptides. Biotechnol. Adv., 2011, 29, 272-277.
25. Agathos, S.N.; Madhosingh, C.; Marshall, J.W.; Lee, J. The fungal production of cyclosporine. Ann. N. Y. Acad. Sci., 1987, 506, 657-662.
26. Oldenburg, K.R.; D'Orfani, A.L.; Selick, H.E. A method for the high-level expression of a parathyroid hormone analog in Escherichia coli. Protein Expression Purif., 1994, 5, 278-284.
27. Roy, S.K. Clinical Pharmacology and Biopharmaceutics Review - Desirudin; U.S. Food and Drug Administration, 2000.
28. Forteo(r) teriparatide (rdna origin) injection; Eli Lilly and Company: Indianapolis, IN 46285, USA, 2002, 2007; pp 1-18.
29. Lehmann, A. Ecallantide (dx-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin. Biol. Ther., 2008, 8, 1187-1199.
30. Won, J.I.; Barron, A.E. A new cloning method for the preparation of long repetitive polypeptides without a sequence requirement. Macromolecules, 2002, 35, 8281-8287.
31. Martemyanov, K.A.; Shirokov, V.A.; Kurnasov, O.V.; Gudkov, A.T.; Spirin, A.S. Cell-free production of biologically active polypeptides: Application to the synthesis of antibacterial peptide cecropin. Protein Expression Purif., 2001, 21, 456-461.
32. Breitling, R.; Klingner, S.; Callewaert, N.; Pietrucha, R.; Geyer, A.; Ehrlich, G.; Hartung, R.; Muller, A.; Contreras, R.; Beverley, S.M.; Alexandrov, K. Non-pathogenic trypanosomatid protozoa as a platform for protein research and production. Protein Expression Purif., 2002, 25, 209-218.
33. Mureev, S.; Kovtun, O.; Nguyen, U.T.T.; Alexandrov, K. Species-independent translational leaders facilitate cell-free expression. Nat. Biotechnol., 2009, 27, 747-798.
34. Wang, K.; Schmied, W.H.; Chin, J.W. Reprogramming the genetic code: From triplet to quadruplet codes. Angew. Chem. Int. Ed., 2012, 51, 2288-2297.
35. Neumann, H.; Wang, K.H.; Davis, L.; Garcia-Alai, M.; Chin, J.W. Encoding multiple unnatural amino acids via evolution of a quadruplet-decoding ribosome. Nature, 2010, 464, 441-444.
36. Murray, B.A.; FitzGerald, R.J. Angiotensin converting enzyme inhibitory peptides derived from food proteins: Biochemistry, bioactivity and production. Curr. Pharm. Des., 2007, 13, 773-791.
37. Gill, H.S.; Doull, F.; Rutherfurd, K.J.; Cross, M.L. Immunoregulatory peptides in bovine milk. B r. J. Nutr., 2000, 84 Suppl 1, S111-117.
38. Hartmann, R.; Meisel, H. Food-derived peptides with biological activity: From research to food applications. Curr. Opin. Biotechnol., 2007, 18, 163-169.
39. Bourgeaux, V.; Cadene, M.; Piller, F.; Piller, V. Efficient enzymatic glycosylation of peptides and oligosaccharides from GalNAc and UTP. ChemBioChem, 2007, 8, 37-40.
40. Merkler, D.J. C-terminal amidated peptides - production by the in-vitro enzymatic amidation of glycine-extended peptides and the importance of the amide to bioactivity. Enzyme Microb. Technol., 1994, 16, 450-456.
41. Knudsen, L.B.; Nielsen, P.F.; Huusfeldt, P.O.; Johansen, N.L.; Madsen, K.; Pedersen, F.Z.; Thogersen, H.; Wilken, M.; Agerso, H. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J. Med. Chem., 2000, 43, 1664-1669.
42. Drucker, D.J.; Drutselis, A.; Kirkpatrick, P. Fresh from the pipeline. Liraglutide. Nat. Rev. Drug Discov., 2010, 9, 267-268.
43. Leadbetter, M.R.; Adams, S.M.; Bazzini, B.; Fatheree, P.R.; Karr, D.E.; Krause, K.M.; Lam, B.M.; Linsell, M.S.; Nodwell, M.B.; Pace, J.L.; Quast, K.; Shaw, J.P.; Soriano, E.; Trapp, S.G.; Villena, J.D.; Wu, T.X.; Christensen, B.G.; Judice, J.K. Hydrophobic vancomycin derivatives with improved ADME properties: Discovery of telavancin (TD-6424). The Journal of Antibiotics, 2004, 57, 326-336.
44. Babiuk, L.A. Broadening the approaches to developing more effective vaccines. Vaccine, 1999, 17, 1587-1595.
45. Moyle, P.M.; Toth, I. Self-adjuvanting lipopeptide vaccines. Curr. Med. Chem., 2008, 15, 506-516.
46. Moyle, P.M.; McGeary, R.P.; Blanchfield, J.T.; Toth, I. Mucosal immunisation: Adjuvants and delivery systems. Curr. Drug Del., 2004, 1, 385-396.
47. Tam, J.P. Synthetic peptide vaccine design: Synthesis and properties of a high-density multiple antigenic peptide system. Proc. Natl. Acad. Sci. U. S. A., 1988, 85, 5409-5413.
48. Purcell, A.W.; Croft, N.P. Peptidomimetics: Modifying peptides in the pursuit of better vaccines. Expert Rev. Vaccines, 2011, 10, 211-226.
49. Wiesmuller, K.H.; Jung, G.; Hess, G. Novel low-molecular-weight synthetic vaccine against foot-and-mouth disease containing a potent B-cell and macrophage activator. Vaccine, 1989, 7, 29-33.
50. Zeng, W.G.; Ghosh, S.; Lau, Y.F.; Brown, L.E.; Jackson, D.C. Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J. Immunol., 2002, 169, 4905-4912.
51. Bessler, W.G.; Baier, W.; vd Esche, U.; Hoffmann, P.; Heinevetter, L.; Wiesmuller, K.H.; Jung, G. Bacterial lipopeptides constitute efficient novel immunogens and adjuvants in parenteral and oral immunization. Behring Inst. Mitt., 1997, 390-399.
52. Andrieu, M.; Loing, E.; Desoutter, J.F.; Connan, F.; Choppin, J.; Gras-Masse, H.; Hanau, D.; Dautry-Varsat, A.; Guillet, J.G.; Hosmalin, A. Endocytosis of an HIV-derived lipopeptide into human dendritic cells followed by class I-restricted CD8(+) T lymphocyte activation. Eur. J. Immunol., 2000, 30, 3256-3265.
53. Phillipps, K.S.M.; Wykes, M.N.; Liu, X.Q.; Brown, M.; Blanchfield, J.; Toth, I. A novel synthetic adjuvant enhances dendritic cell function. Immunology, 2009, 128, e582-e588.
54. Olive, C.; Batzloff, M.R.; Toth, I. Lipid core peptide technology and group A streptococcal vaccine delivery. Expert Rev. Vaccines, 2004, 3, 43-58.
55. Olive, C.; Ho, M.F.; Dyer, J.; Lincoln, D.; Barozzi, N.; Toth, I.; Good, M.F. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus. J. Infect. Dis., 2006, 193, 1666-1676.
56. Zhong, G.M.; Toth, I.; Reid, R.; Brunham, R.C. Immunogenicity evaluation of a lipidic amino acid-based synthetic peptide vaccine for chlamydia- trachomatis. J. Immunol., 1993, 151, 3728-3736.
57. Moyle, P.M.; Olive, C.; Ho, M.F.; Pandey, M.; Dyer, J.; Suhrbier, A.; Fujita, Y.; Toth, I. Toward the development of prophylactic and therapeutic human papillomavirus type-16 lipopeptide vaccines. J. Med. Chem., 2007, 50, 4721-4727.
58. Olive, C.; Schulze, K.; Sun, H.K.; Ebensen, T.; Horvath, A.; Toth, I.; Guzman, C.A. Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation. Vaccine, 2007, 25, 1789-1797.
59. Simerska, P.; Abdel-Aal, A.B.; Fujita, Y.; Batzloff, M.R.; Good, M.F.; Toth, I. Synthesis and in vivo studies of carbohydrate-based vaccines against group A streptococcus. Biopolymers, 2008, 90, 611-616.
60. Moyle, P.M.; Olive, C.; Ho, M.F.; Good, M.F.; Toth, I. Synthesis of a highly pure lipid core peptide based self-adjuvanting triepitopic group A streptococcal vaccine, and subsequent immunological evaluation. J. Med. Chem., 2006, 49, 6364-6370.
61. Simerska, P.; Abdel-Aal, A.B.; Fujita, Y.; Moyle, P.M.; McGeary, R.P.; Batzloff, M.R.; Olive, C.; Good, M.F.; Toth, I. Development of a liposaccharide-based delivery system and its application to the design of group A streptococcal vaccines. J. Med. Chem., 2008, 51, 1447-1452.
62. Abdel-Aal, A.B.M.; Zaman, M.; Fujita, Y.; Batzloff, M.R.; Good, M.F.; Toth, I. Design of three-component vaccines against group A streptococcal infections: Importance of spatial arrangement of vaccine components. J. Med. Chem., 2010, 53, 8041-8046.
63. Olive, C.; Moyle, P.M.; Toth, I. Towards the development of a broadly protective group A streptococcal vaccine based on the lipid-core peptide system. Curr. Med. Chem., 2007, 14, 2976-2988.
64. Adams, E.W.; Ratner, D.M.; Seeberger, P.H.; Hacohen, N. Carbohydrate-mediated targeting of antigen to dendritic cells leads to enhanced presentation of antigen to T cells. ChemBioChem, 2008, 9, 294-303.
65. Cui, Z.G.; Han, S.J.; Huang, L. Coating of mannan on LPD particles containing HPV E7 peptide significantly enhances immunity against HPV-positive tumor. Pharm. Res., 2004, 21, 1018-1025.
66. Skwarczynski, M.; Toth, I. Peptide-based subunit nanovaccines. Curr. Drug Del., 2011, 8, 282-289.
67. Zaman, M.; Skwarczynski, M.; Malcolm, J.M.; Urbani, C.N.; Jia, Z.F.; Batzloff, M.R.; Good, M.F.; Monteiro, M.J.; Toth, I. Self-adjuvanting polyacrylic nanoparticulate delivery system for group A streptococcus (gas) vaccine. Nanomed. Nanotechnol. Biol. Med., 2011, 7, 168-173.
68. Skwarczynski, M.; Zaman, M.; Urbani, C.N.; Lin, I.C.; Jia, Z.F.; Batzloff, M.R.; Good, M.F.; Monteiro, M.F.; Toth, I. Polyacrylate dendrimer nanoparticles: A self-adjuvanting vaccine delivery system. Angew. Chem. Int. Ed., 2010, 49, 5742-5745.
69. McNeela, E.A.; Lavelle, E.C. Recent advances in microparticle and nanoparticle delivery vehicles for mucosal vaccination. Curr. Top. Microbiol. Immunol., 2012, 354, 75-99.
70. Woodley, J.F. Enzymatic barriers for GI peptide and protein delivery. Crit. Rev. Ther. Drug Carrier Syst., 1994, 11, 61-95.
71. Kawakami, T.; Kamo, M.; Takamoto, K.; Miyazaki, K.; Chow, L.P.; Ueno, Y.; Tsugita, A. Bond-specific chemical cleavages of peptides and proteins with perfluoric acid vapors: Novel peptide bond cleavages of glycyl-threonine, the amino side of serine residues and the carboxyl side of aspartic acid residues. J. Biochem., 1997, 121, 68-76.
72. Vlieghe, P.; Lisowski, V.; Martinez, J.; Khrestchatisky, M. Synthetic therapeutic peptides: Science and market. Drug Discov. Today, 2010, 15, 40-56.
73. Barberi-Heyob, M.; Pernot, M.; Vanderesse, R.; Frochot, C.; Guillemin, F. Stability of peptides and therapeutic success in cancer. Expert Opin. Drug Metab. Toxicol., 2011, 7, 793-802.
74. Nguyen, L.T.; Chau, J.K.; Perry, N.A.; de Boer, L.; Zaat, S.A.J.; Vogel, H.J. Serum stabilities of short tryptophan-and arginine-rich antimicrobial peptide analogs. PLoS ONE, 2010, 5, e12684. doi:10.1371/journal.pone.0012684.
75. Zhang, G.H.; Han, B.Z.; Lin, X.Y.; Wu, X.; Yan, H.S. Modification of antimicrobial peptide with low molar mass poly(ethylene glycol). J. Biochem., 2008, 144, 781-788.
76. Bergeon, J.A.; Chan, Y.N.; Charles, B.G.; Toth, I. Oral absorption enhancement of dipeptide l-Glu-l-Trp-OH by lipid and glycosyl conjugation. Biopolymers, 2008, 90, 633-643.
77. Nomoto, M.; Yamada, K.; Haga, M.; Hayashi, M. Improvement of intestinal absorption of peptide drugs by glycosylation: Transport of tetrapeptide by the sodium ion-dependent D-glucose transporter. J. Pharm. Sci., 1998, 87, 326-332.
78. Egleton, R.D.; Mitchell, S.A.; Huber, J.D.; Palian, M.M.; Polt, R.; Davis, T.P. Improved blood-brain barrier penetration and enhanced analgesia of an opioid peptide by glycosylation. J. Pharmacol. Exp. Ther., 2001, 299, 967-972.
79. Foldvari, M.; Baca-Estrada, M.E.; He, Z.H.; Hu, J.P.; Attah-Poku, S.; King, M. Dermal and transdermal delivery of protein pharmaceuticals: Lipid-based delivery systems for interferon alpha. Biotechnol. Appl. Biochem., 1999, 30, 129-137.
80. Wollmer, P.; Pieber, T.R.; Gall, M.A.; Brunton, S. Delivering needle-free insulin using AERx iDMS (insulin diabetes management system) technology. Diabetes Technol. Ther., 2007, 9 Suppl 1, S57-64.
81. Hamman, J.H.; Enslin, G.M.; Kotze, A.F. Oral delivery of peptide drugs -barriers and developments. BioDrugs, 2005, 19, 165-177.
82. Huzil, J.T.; Sivaloganathan, S.; Kohandel, M.; Foldvari, M. Drug delivery through the skin: Molecular simulations of barrier lipids to design more effective noninvasive dermal and transdermal delivery systems for small molecules, biologics, and cosmetics. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 2011, 3, 449-462.
83. Chen, X.; Fernando, G.J.P.; Crichton, M.L.; Flaim, C.; Yukiko, S.R.; Fairmaid, E.J.; Corbett, H.J.; Primiero, C.A.; Ansaldo, A.B.; Frazer, I.H.; Brown, L.E.; Kendall, M.A.F. Improving the reach of vaccines to low-resource regions, with a needle-free vaccine delivery device and long-term thermostabilization. J. Controlled Release, 2011, 152, 349-355.
84. Scheuch, G.; Siekmeier, R. Novel approaches to enhance pulmonary delivery of proteins and peptides. J. Physiol. Pharmacol., 2007, 58, 615-625.
85. Bailey, C.J.; Barnett, A.H. Why is Exubera being withdrawn? B r. Med. J., 2007, 335, 1156-1156.
86. Chung, S.W.; Hil-lal, T.A.; Byun, Y. Strategies for non-invasive delivery of biologics. J. Drug Targeting, 2012, 20, 481-501.
87. du Plessis, L.H.; Kotze, A.F.; Junginger, H.E. Nasal and rectal delivery of insulin with chitosan and N-trimethyl chitosan chloride. Drug Deliv., 2010, 17, 399-407.
88. Zhang, X.G.; Zhang, H.J.; Wu, Z.M.; Wang, Z.; Niu, H.M.; Li, C.X. Nasal absorption enhancement of insulin using PEG-grafted chitosan nanoparticles. Eur. J. Pharm. Biopharm., 2008, 68, 526-534.
89. Dufes, C.; Olivier, J.C.; Gaillard, F.; Gaillard, A.; Couet, W.; Muller, J.M. Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats. Int. J. Pharm., 2003, 255, 87-97.
90. Antosova, Z.; Mackova, M.; Kral, V.; Macek, T. Therapeutic application of peptides and proteins: Parenteral forever? Trends Biotechnol., 2009, 27, 628-635.
91. Rose, E.H.; Aledort, L.M. Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease. Ann. Intern. Med., 1991, 114, 563-568.
92. Toth, I.; Flinn, N.; Hillery, A.; Gibbons, W.A.; Artursson, P. Lipidic conjugates of luteinizing-hormone-releasing hormone (LHRH)+ and thyrotropin-releasing-hormone (TRH)+ that release and protect the native hormones in homogenates of human intestinal epithelial (CACO-2) cells. Int. J. Pharm., 1994, 105, 241-247.
93. Bundgaard, H.; Hansen, A.B. Pro-drugs as drug delivery systems. Pharm. Int., 1981, 2, 136-140.
94. Testa, B. Prodrugs: Bridging pharmacodynamic/pharmacokinetic gaps. Curr. Opin. Chem. Biol., 2009, 13, 338-344.
95. Hsieh, P.W.; Hung, C.F.; Fang, J.Y. Current prodrug design for drug discovery. Curr. Pharm. Des., 2009, 15, 2236-2250.
96. Blanchfield, J.T.; Lew, R.A.; Smith, A.I.; Toth, I. The stability of lipidic analogues of GnRH in plasma and kidney preparations: The stereoselective release of the parent peptide. Bioorg. Med. Chem. Lett., 2005, 15, 1609-1612.
97. Ferdinandi, E.S.; Brazeau, P.; High, K.; Procter, B.; Fennell, S.; Dubreuil, P. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin. Pharmacol. Toxicol., 2007, 100, 49-58.
98. Koda, Y.; Liang, M.T.; Blanchfield, J.T.; Toth, I. In vitro stability and permeability studies of liposomal delivery systems for a novel lipophilic endomorphin 1 analogue. Int. J. Pharm., 2008, 356, 37-43.
99. Toth, I.; Hillery, A.M.; Wood, I.P.; Magnusson, C.; Artursson, P. Oral absorption of lipidic amino-acid conjugates. Int. J. Pharm., 1994, 102, 223-230.
100. Uchiyama, T.; Kotani, A.; Tatsumi, H.; Kishida, T.; Okamoto, A.; Okada, N.; Murakami, M.; Fujita, T.; Fujiwara, Y.; Kiso, Y.; Muranishi, S.; Yamamoto, A. Development of novel lipophilic derivatives of DADLE (leucine enkephalin analogue): Intestinal permeability characteristics of DADLE derivatives in rats. Pharm. Res., 2000, 17, 1461-1467.
101. Fredholt, K.; Adrian, C.; Just, L.; Larsen, D.H.; Weng, S.S.; Moss, B.; Friis, G.J. Chemical and enzymatic stability as well as transport properties of a leuenkephalin analogue and ester prodrugs thereof. J. Controlled Release, 2000, 63, 261-273.
102. Kellam, B.; Drouillat, B.; Dekany, G.; Starr, M.S.; Toth, I. Synthesis and in vitro evaluation of lipoamino acid and carbohydrate-modified enkephalins as potential antinociceptive agents. Int. J. Pharm., 1998, 161, 55-64.
103. Drouillat, B.; Hillery, A.M.; Dekany, G.; Falconer, R.; Wright, K.; Toth, I. Novel liposaccharide conjugates for drug and peptide delivery. J. Pharm. Sci., 1998, 87, 25-30.
104. Wessling, S.T.; Ross, B.P.; Koda, Y.; Blanchfield, J.T.; Toth, I. CACO-2 cell permeability and stability of two D-glucopyranuronamide conjugates of thyrotropin-releasing hormone. Biorg. Med. Chem., 2007, 15, 4946-4950.
105. Toth, I.; Malkinson, J.P.; Flinn, N.S.; Drouillat, B.; Horvath, A.; Erchegyi, J.; Idei, M.; Venetianer, A.; Artursson, P.; Lazorova, L.; Szende, B.; Keri, G. Novel lipoamino acid- and liposaccharide-based system for peptide delivery: Application for oral administration of tumor-selective somatostatin analogues. J. Med. Chem., 1999, 42, 4010-4013.
106. Suzuki, K.; Susaki, H.; Okuno, S.; Yamada, H.; Watanabe, H.K.; Sugiyama, Y. Specific renal delivery of sugar-modified low-molecular-weight peptides. J. Pharmacol. Exp. Ther., 1999, 288, 888-897.
107. Zhou, N.M.; Luo, Z.W.; Luo, J.S.; Fan, X.J.; Cayabyab, M.; Hiraoka, M.; Liu, D.X.; Han, X.B.; Pesavento, J.; Dong, C.Z.; Wang, Y.L.; An, J.; Kaji, H.; Sodroski, J.G.; Huang, Z.W. Exploring the stereochemistry of CXCR4-peptide recognition and inhibiting HIV-1 entry with D-peptides derived from chemokines. J. Biol. Chem., 2002, 277, 17476-17485.
108. De Zotti, M.; Biondi, B.; Peggion, C.; Park, Y.; Hahm, K.S.; Formaggio, F.; Toniolo, C. Synthesis, preferred conformation, protease stability, and membrane activity of heptaibin, a medium-length peptaibiotic. J. Pept. Sci., 2011, 17, 585-594.
109. Bork, K.; Yasothan, U.; Kirkpatrick, P. Fresh from the pipeline. Icatibant. Nat. Rev. Drug Discov., 2008, 7, 801-802.
110. Taylor, M.; Moore, S.; Mayes, J.; Parkin, E.; Beeg, M.; Canovi, M.; Gobbi, M.; Mann, D.M.A.; Allsop, D. Development of a proteolytically stable retro-inverso peptide inhibitor of beta-amyloid oligomerization as a potential novel treatment for alzheimer's disease. Biochemistry (Mosc). 2010, 49, 3261-3272.
111. Liebmann, C.; Szucs, M.; Neubert, K.; Hartrodt, B.; Arold, H.; Barth, A. Opiate receptor-binding affinities of some D-amino-acid substituted beta-casomorphin analogs. Peptides, 1986, 7, 195-199.
112. Garcia-Echeverria, C.; Chene, P.; Blommers, M.J.J.; Furet, P. Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53. J. Med. Chem., 2000, 43, 3205-3208.
113. Liskamp, R.M.J.; Rijkers, D.T.S.; Kruijtzer, J.A.W.; Kemmink, J. Peptides and proteins as a continuing exciting source of inspiration for peptidomimetics. ChemBioChem, 2011, 12, 1626-1653.
114. Zuckermann, R.N.; Kerr, J.M.; Kent, S.B.H.; Moos, W.H. Efficient method for the preparation of peptoids [Oligo(N-substituted glycines)] by submonomer solid-phase synthesis. J. Am. Chem. Soc., 1992, 114, 10646-10647.
115. Miller, S.M.; Simon, R.J.; Ng, S.; Zuckermann, R.N.; Kerr, J.M.; Moos, W.H. Comparison of the proteolytic susceptibilities of homologous L-amino-acid, D-amino-acid, and N-substituted glycine peptide and peptoid oligomers. Drug Dev. Res., 1995, 35, 20-32.
116. Bang, J.K.; Nan, Y.H.; Lee, E.K.; Shin, S.Y. A novel Trp-rich model antimicrobial peptoid with increased protease stability. Bull. Korean Chem. Soc., 2010, 31, 2509-2513.
117. Kim, J.M.; Bi, Y.Z.; Paikoff, S.J.; Schultz, P.G. The solid phase synthesis of oligoureas. Tetrahedron Lett., 1996, 37, 5305-5308.
118. Cho, C.Y.; Liu, C.W.; Wemmer, D.E.; Schultz, P.G. Cyclic and linear oligocarbamate ligands for human thrombin. Biorg. Med. Chem., 1999, 7, 1171-1179.
119. deBont, D.B.A.; Moree, W.J.; Liskamp, R.M.J. Molecular diversity of peptidomimetics: Approaches to the solid-phase synthesis of peptidosulfonamides. Biorg. Med. Chem., 1996, 4, 667-672.
120. Claudon, P.; Violette, A.; Lamour, K.; Decossas, M.; Fournel, S.; Heurtault, B.; Godet, J.; Mely, Y.; Jamart-Gregoire, B.; Averlant-Petit, M.C.; Briand, J.P.; Duportail, G.; Monteil, H.; Guichard, G. Consequences of isostructural main-chain modifications for the design of antimicrobial foldamers: Helical mimics of host-defense peptides based on a heterogeneous amide/urea backbone. Angew. Chem. Int. Ed., 2010, 49, 333-336.
121. Seebach, D.; Overhand, M.; Kuhnle, F.N.M.; Martinoni, B.; Oberer, L.; Hommel, U.; Widmer, H. Beta-peptides: Synthesis by Arndt-Eistert homologation with concomitant peptide coupling. Structure determination by NMR and CD spectroscopy and by X-ray crystallography. Helical secondary structure of a beta-hexapeptide in solution and its stability towards pepsin. Helv. Chim. Acta, 1996, 79, 913-941.
122. Elgersma, R.C.; Meijneke, T.; de Jong, R.; Brouwer, A.J.; Posthuma, G.; Rijkers, D.T.S.; Liskamp, R.M.J. Synthesis and structural investigations of N-alkylated beta-peptidosulfonamide-peptide hybrids of the amyloidogenic amylin(20-29) sequence: Implications of supramolecular folding for the design of peptide-based bionanomaterials. Org. Biomol. Chem., 2006, 4, 3587-3597.
123. Muttenthaler, M.; Andersson, A.; de Araujo, A.D.; Dekan, Z.; Lewis, R.J.; Alewood, P.F. Modulating oxytocin activity and plasma stability by disulfide bond engineering. J. Med. Chem., 2010, 53, 8585-8596.
124. Malik, D.K.; Baboota, S.; Ahuja, A.; Hasan, S.; Ali, J. Recent advances in protein and peptide drug delivery systems. Curr. Drug Del., 2007, 4, 141-151.
125. Toledano, Y.; Rot, L.; Greenman, Y.; Orlovsky, S.; Pauker, Y.; Olchovsky, D.; Eliash, A.; Bardicef, O.; Makhoul, O.; Tsvetov, G.; Gershinsky, M.; Cohen-Ouaqnine, O.; Ness-Abramof, R.; Adnan, Z.; Ilany, J.; Guttmann, H.; Sapir, M.; Benbassat, C.; Shimon, I. Efficacy of long-term lanreotide treatment in patients with acromegaly. Pituitary, 2009, 12, 285-293.
126. Alyautdin, R.; Gothier, D.; Petrov, V.; Kharkevich, D.; Kreuter, J. Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles. Eur. J. Pharm. Biopharm., 1995, 41, 44-48.
127. Koren, E.; Apte, A.; Sawant, R.R.; Grunwald, J.; Torchilin, V. P. Cell-penetrating TAT peptide in drug delivery systems: Proteolytic stability requirements. Drug Deliv., 2011, 18, 377-384.
128. Rousselle, C.; Clair, P.; Smirnova, M.; Kolesnikov, Y.; Pasternak, G.W.; Gac-Breton, S.; Rees, A.R.; Scherrmann, J.M.; Temsamani, J. Improved brain uptake and pharmacological activity of dalargin using a peptide-vector-mediated strategy. J. Pharmacol. Exp. Ther., 2003, 306, 371-376.
129. Bickel, U.; Kang, Y.S.; Pardridge, W.M. In vivo cleavability of a disulfide-based chimeric opioid peptide in rat brain. Bioconj. Chem., 1995, 6, 211-218.
130. Kumagai, A.K.; Eisenberg, J.B.; Pardridge, W.M. Absorptive-mediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries - model system of blood-brain-barrier transport. J. Biol. Chem., 1987, 262, 15214-15219.
131. Chandna, P.; Khandare, J.J.; Ber, E.; Rodriguez-Rodriguez, L.; Minko, T. Multifunctional tumor-targeted polymer-peptide-drug delivery system for treatment of primary and metastatic cancers. Pharm. Res., 2010, 27, 2296-2306.
132. Hatakeyama, S.; Sugihara, K.; Shibata, T.K.; Nakayama, J.; Akama, T.O.; Tamura, N.; Wong, S.M.; Bobkov, A.A.; Takano, Y.; Ohyama, C.; Fukuda, M.; Fukuda, M.N. Targeted drug delivery to tumor vasculature by a carbohydrate mimetic peptide. Proc. Natl. Acad. Sci. U. S. A., 2011, 108, 19587-19592.
133. Dufort, S.; Sancey, L.; Hurbin, A.; Foillard, S.; Boturyn, D.; Dumy, P.; Coll, J.L. Targeted delivery of a proapoptotic peptide to tumors in vivo. J. Drug Targeting, 2011, 19, 582-588.
134. White, C.J.; Yudin, A.K. Contemporary strategies for peptide macrocyclization. Nat. Chem., 2011, 3, 509-524.
135. Tugyi, R.; Mezo, G.; Fellinger, E.; Andreu, D.; Hudecz, F. The effect of cyclization on the enzymatic degradation of herpes simplex virus glycoprotein d derived epitope peptide. J. Pept. Sci., 2005, 11, 642-649.
136. Rink, R.; Arkema-Meter, A.; Baudoin, I.; Post, E.; Kuipers, A.; Nelemans, S.A.; Akanbi, M.H.J.; Moll, G.N. To protect peptide pharmaceuticals against peptidases. J. Pharmacol. Toxicol. Methods, 2010, 61, 210-218.
137. Berezowska, I.; Chung, N.N.; Lemieux, C.; Wilkes, B.C.; Schiller, P.W. Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[D-Cys-Gly-Phe-D(orL) -Cys]NH2 retain high opioid activity. J. Med. Chem., 2007, 50, 1414-1417.
138. Stymiest, J.L.; Mitchell, B.F.; Wong, S.; Vederas, J.C. Synthesis of oxytocin analogues with replacement of sulfur by carbon gives potent antagonists with increased stability. J. Org. Chem., 2005, 70, 7799-7809.
139. Robinson, A.J.; Elaridi, J.; Van Lierop, B.J.; Mujcinovic, S.; Jackson, W.R. Microwave-assisted RCM for the synthesis of carbocyclic peptides. J. Pept. Sci., 2007, 13, 280-285.
140. Whelan, A.N.; Elaridi, J.; Mulder, R.J.; Robinson, A.J.; Jackson, W.R. Metal-catalysed tandem metathesis-hydrogenation reactions for the synthesis of carba analogues of cyclic peptides. Can. J. Chem., 2005, 83, 875-881.
141. Clark, R.J.; Akcan, M.; Kaas, Q.; Daly, N.L.; Craik, D.J. Cyclization of conotoxins to improve their biopharmaceutical properties. Toxicon, 2012, 59, 446-455.
142. Walensky, L.D.; Kung, A.L.; Escher, I.; Malia, T.J.; Barbuto, S.; Wright, R.D.; Wagner, G.; Verdine, G.L.; Korsmeyer, S.J. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science, 2004, 305, 1466-1470.
143. Sando, L.; Henriques, S.T.; Foley, F.; Simonsen, S.M.; Daly, N.L.; Hall, K.N.; Gustafson, K.R.; Aguilar, M.I.; Craik, D.J. A synthetic mirror image of kalata b1 reveals that cyclotide activity is independent of a protein receptor. ChemBioChem, 2011, 12, 2456-2462.
144. Bernal, F.; Tyler, A.F.; Korsmeyer, S.J.; Walensky, L.D.; Verdine, G.L. Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. J. Am. Chem. Soc., 2007, 129, 5298-5298.
145. Bird, G.H.; Madani, N.; Perry, A.F.; Princiotto, A.M.; Supko, J.G.; He, X.Y.; Gavathiotis, E.; Sodroski, J.G.; Walensky, L.D. Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic. Proc. Natl. Acad. Sci. U. S. A., 2010, 107, 14093-14098.
146. Wong, A.K.; Ross, B.P.; Chan, Y.N.; Artursson, P.; Lazorova, L.; Jones, A.; Toth, I. Determination of transport in the CACO-2 cell assay of compounds varying in lipophilicity using LC-MS: Enhanced transport of leu-enkephalin analogues. Eur. J. Pharm. Sci., 2002, 16, 113-118.
147. Wu, S.; Campbell, C.; Koda, Y.; Blanchfield, J.T.; Toth, I. Investigation of the route of absorption of lipid and sugar modified leu-enkephalin analogues and their enzymatic stability using the CACO-2 cell monolayer system. Med. Chem., 2006, 2, 203-211.
148. Elmagbari, N.O.; Egleton, R.D.; Palian, M.M.; Lowery, J.J.; Schmid, W.R.; Davis, P.; Navratilova, E.; Dhanasekaran, M.; Keyari, C.M.; Yamamura, H.I.; Porreca, F.; Hruby, V.J.; Polt, R.; Bilsky, E.J. Antinociceptive structure-activity studies with enkephalin-based opioid glycopeptides. J. Pharmacol. Exp. Ther., 2004, 311, 290-297.
149. Stoermer, M.J.; Flanagan, B.; Beyer, R.L.; Madala, P.K.; Fairlie, D.P. Structures of peptide agonists for human protease activated receptor 2. Bioorg. Med. Chem. Lett., 2012, 22, 916-919.
150. Morrison, K.L.; Weiss, G.A. Combinatorial alanine-scanning. Curr. Opin. Chem. Biol., 2001, 5, 302-307.
151. Hruby, V.J. Designing peptide receptor agonists and antagonists. Nat. Rev. Drug Discov., 2002, 1, 847-858.
152. Savio, A.S.; Acosta, O.R.; Perez, H.G.; Alvarez, Y.R.; Chico, A.; Perez, H.G.; Ojeda, M.O.; Aguero, C.A.; Estevez, M.; Nieto, G.G. Enhancement of the inhibitory effect of an IL-15 antagonist peptide by alanine scanning. J. Pept. Sci., 2012, 18, 25-29.
153. U.S. National Institutes of Health. ClinicalTrials.gov. http://clinicaltrials.gov (Accessed June 25, 2012).